Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.

doi:10.1016/j.ccell.2016.03.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.

Cancer cell - 11 Apr 2016

Brien Gerard L, Valerio Daria G, Armstrong Scott A

Abstract excerpt

The epigenome is a key determinant of transcriptional output. Perturbations within the epigenome are thought to be a key feature of many, perhaps all cancers, and it is now clear that epigenetic changes are instrumental in cancer development. The inherent reversibility of these changes makes them attractive targets for therapeutic manipulation, and a number of small molecules targeting chromatin-based mechanisms...

Topics

Animals
Antineoplastic Agents
Cell Transformation, Neoplastic
Chromatin
Chromosome Aberrations
Clinical Trials as Topic
DNA Methylation
DNA, Neoplasm
Drug Resistance, Neoplasm
Epigenesis, Genetic
Epigenomics
Gene Expression Regulation, Neoplastic
Histone Code

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Histone Deacetylase Inhibitors

Histones

Humans

Mice

Models, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 27070701
DOI: 10.1016/j.ccell.2016.03.007
PMCID: PMC4889129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.